BioWorld

Nov. 4, 2008

View Archived Issues

Telaprevir Takes Center Stage as New HCV Approaches Advance

As analysts predicted, the data coming out of embargo during the annual meeting of the American Association for the Study of Liver Disease (AASLD) don't appear to be triggering any major swings in biotech stock prices. (BioWorld Today) Read More

Top FDA Career Officials Opposed Preemption Rules

Read More

Scientists Target Immune System Microenvironment to Strike Tumor

Read More

Genentech Seeks Avastin Use for Aggressive Brain Cancer

Read More

Avigen Cutting Staff 70% After Tolperisone Failure

Read More

Cephalon's Treanda OK'd for Second Cancer Indication

Read More

Clinic Roundup

Read More

Other News To Note

Read More